Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4: Adagrasib plus pembrolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in first-line KRAS G12C-mutated non-squamous NSCLC
2024-515698-85-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Adagrasib + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Planned start Jun 2025; status: authorised.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515698-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515698-85-00.